Does Medicare Cover GLP-1 Weight Loss Drugs in 2026?
Wondering if you qualify for Medicare GLP-1 coverage? Talk with DevotedDOc today.
Many Medicare beneficiaries have been asking the same question: Does Medicare cover GLP-1 weight loss drugs in 2026? The answer is yes—for some people. Beginning July 1, 2026, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge Program, a temporary nationwide demonstration that expands access to certain GLP-1 medications for eligible Medicare Part D beneficiaries who are using these medications for weight management.
The program represents one of the biggest changes to Medicare GLP-1 coverage in recent years. Eligible beneficiaries may receive covered medications such as Wegovy®, Zepbound®, and Foundayo® for a $50 monthly copayment, provided they meet the program’s clinical criteria and receive prior authorization.
However, not everyone with Medicare qualifies. Eligibility depends on factors such as body mass index (BMI), certain health conditions, the reason the medication is prescribed, and the type of Medicare drug coverage you have.
This guide explains how the Medicare GLP-1 Bridge Program works, who qualifies, which medications are covered, how prior authorization works, and what patients should know before discussing treatment with a healthcare provider.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge Program is a temporary demonstration created by CMS to provide eligible Medicare Part D beneficiaries with access to certain GLP-1 medications used to reduce excess body weight and maintain weight loss.
According to CMS Medicare GLP-1 Bridge guidance, the program:
- Begins July 1, 2026
- Continues through December 31, 2027
- Is available nationwide
- Requires prior authorization
- Has a $50 monthly copayment for eligible medications
Unlike traditional Medicare Part D coverage, the Medicare GLP-1 Bridge operates outside the normal Part D payment system. CMS manages prior authorization, claims processing, and pharmacy reimbursement through a centralized system during the demonstration period.
The program also allows CMS to collect data that may help shape future Medicare coverage policies for obesity treatment after the demonstration ends.
Who Qualifies for the Medicare GLP-1 Bridge?
Not everyone enrolled in Medicare automatically qualifies for the program.
According to Medicare.gov weight loss drug coverage information, patients must:
- Be 18 years or older
- Have eligible Medicare Part D prescription drug coverage
- Receive a prescription for an approved GLP-1 medication specifically for weight management
- Participate in an ongoing lifestyle program that includes nutrition and physical activity
- Meet one of the following clinical criteria:
BMI of 35 or Higher
Adults with a body mass index (BMI) of 35 or greater may qualify.
BMI Between 30 and 34.99 With Certain Medical Conditions
Patients with a BMI between 30 and 34.99 must also have at least one qualifying condition, such as:
- Heart failure with preserved ejection fraction
- Uncontrolled hypertension
- Chronic kidney disease stage 3a or higher
- Prediabetes
BMI Between 27 and 29.99 With Certain Cardiovascular Conditions
Patients with a BMI between 27 and 29.99 may qualify if they have:
- Prediabetes
- Previous heart attack
- Previous stroke
- Symptomatic peripheral artery disease
Who Is Not Eligible?
Some Medicare beneficiaries are not eligible for the Medicare GLP-1 Bridge.
For example, individuals already receiving GLP-1 medications through standard Medicare Part D coverage for FDA-approved conditions such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis (MASH) generally continue receiving coverage through their Part D plan rather than through the Bridge Program.
Which GLP-1 Medications Are Covered?
Beginning July 1, 2026, CMS currently lists the following medications as eligible under the demonstration:
| Medication | Covered Under Medicare GLP-1 Bridge? | Notes |
| Wegovy® | Yes | Injection and tablet formulations |
| Zepbound® | Yes | KwikPen® formulation only |
| Foundayo® | Yes | FDA-approved formulations |
| Ozempic® | Usually no | Generally covered only for FDA-approved indications such as type 2 diabetes |
Many people search “Does Medicare cover Wegovy?” or “Does Medicare cover Zepbound?” The answer is yes for eligible beneficiaries participating in the Medicare GLP-1 Bridge Program, provided all program requirements are met.
Patients comparing treatment options may also want to review Zepbound effectiveness for weight loss and learn what realistic Zepbound weight loss results may look like before discussing medication with a healthcare provider.
How Does Prior Authorization Work?
Receiving a prescription alone does not automatically mean Medicare will cover a GLP-1 medication. CMS requires prior authorization before coverage is approved. During the prior authorization process, your healthcare provider typically documents several key details.
Medical Eligibility
Your provider confirms that you meet the program’s BMI and clinical criteria. This may include documenting your current BMI, age, Medicare drug coverage, and any qualifying health conditions required by the Medicare GLP-1 Bridge Program.
Medical Necessity
Documentation must show that the medication is being prescribed for weight reduction consistent with the FDA-approved indication. Your provider may also explain why a GLP-1 medication is medically appropriate based on your health history, weight-related risks, and treatment goals.
Lifestyle Program Participation
Providers must certify that the medication will be used alongside ongoing nutrition and physical activity efforts. This means GLP-1 treatment is not viewed as a stand-alone solution, but as part of a broader weight management plan.
Prescription Submission
Once eligibility is confirmed, your provider submits the prescription and completes the required prior authorization documentation. Approval depends on Medicare GLP-1 Bridge requirements, individual insurance details, and whether the submitted information supports medical necessity.
If approved, Medicare states that the authorization generally remains valid through December 31, 2027, including refills and dose adjustments, unless you switch to another covered GLP-1 medication.
If you’re interested in GLP-1 through telehealth, DevotedDOc physicians can evaluate whether you may qualify, review your medical history, discuss available treatment options, and assist with the prior authorization process when medically appropriate.
Why Medical Weight Management Still Matters
GLP-1 medications can be helpful for some patients, but they work best as part of a broader weight management plan. Medicare also requires eligible patients to use these medications alongside lifestyle changes focused on nutrition and physical activity.
A medically supervised medical weight loss program can help patients understand their options, review health risks, monitor progress, and build a treatment plan that fits their needs.
For organizations and care teams, structured obesity and weight care management can also support long-term health goals for patients managing obesity-related risks.
What Happens After December 31, 2027?
The Medicare GLP-1 Bridge Program is currently scheduled to end on December 31, 2027.
CMS has stated that the demonstration will help collect information on GLP-1 utilization while policymakers evaluate future Medicare coverage models, including the proposed BALANCE Model.
At this time, no final decision has been announced regarding long-term Medicare coverage after the demonstration concludes.
Patients should continue monitoring CMS announcements because eligibility requirements and coverage policies may evolve.
Frequently Asked Questions
Yes. Eligible beneficiaries may receive Wegovy® through the Medicare GLP-1 Bridge Program beginning July 1, 2026, if they meet all clinical requirements.
Yes. The KwikPen® formulation of Zepbound® is covered for eligible beneficiaries through the Medicare GLP-1 Bridge Program.
It is a temporary CMS demonstration that expands access to certain GLP-1 weight loss medications for eligible Medicare Part D beneficiaries between July 1, 2026, and December 31, 2027.
The program officially began on July 1, 2026.
The current demonstration is scheduled to end on December 31, 2027.
Yes. Eligible beneficiaries pay a $50 monthly copayment for covered medications furnished through the Medicare GLP-1 Bridge Program.
Yes. A healthcare provider must submit a prior authorization request and certify that you meet the program’s eligibility requirements.
Yes. Licensed healthcare providers offering telehealth services may evaluate eligible patients, prescribe GLP-1 medications when clinically appropriate, and assist with prior authorization requirements.
Many Medicare Advantage plans that include Part D prescription coverage participate in the demonstration if beneficiaries meet the eligibility requirements.
If coverage is denied, your healthcare provider may review the reason for the denial, determine whether additional documentation is needed, or discuss alternative treatment options that may be appropriate for your situation.
For additional patient questions, you can also visit DevotedDOc’s frequently asked questions page.
Learn Whether You May Qualify for Medicare GLP-1 Coverage with DevotedDOc
Understanding the Medicare GLP-1 Bridge Program can feel overwhelming, especially if you’re trying to determine whether you qualify for Wegovy®, Zepbound®, or another covered medication.
If you’re interested in learning whether you may qualify for the Medicare GLP-1 Bridge Program or another medically appropriate weight management option, DevotedDOc’s board-certified physicians can review your medical history, discuss your treatment options, determine whether you may be eligible, and assist with prior authorization when clinically appropriate.
Initial physician consultation: $99
Ongoing membership: $49.99/month
Schedule a consultation to learn more about your options for medically supervised weight management.